Lomustine - CAS 13010-47-4
Catalog number:
13010-47-4
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C9H16ClN3O2
Molecular Weight:
233.7
COA:
Inquire
Targets:
DNA Alkylator/Crosslinker
Description:
Lomustine (420 μM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
nsc79037
MSDS:
Inquire
1.Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort.
Chow EJ1, Stratton KL2, Leisenring WM2, Oeffinger KC3, Sklar CA3, Donaldson SS4, Ginsberg JP5, Kenney LB6, Levine JM7, Robison LL8, Shnorhavorian M9, Stovall M10, Armstrong GT8, Green DM8. Lancet Oncol. 2016 Mar 22. pii: S1470-2045(16)00086-3. doi: 10.1016/S1470-2045(16)00086-3. [Epub ahead of print]
BACKGROUND: The effect of many contemporary chemotherapeutic drugs on pregnancy and livebirth is not well established. We aimed to establish the effects of these drugs on pregnancy in male and female survivors of childhood cancer not exposed to pelvic or cranial radiotherapy.
2.Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.
Fisusi FA1, Siew A1, Chooi KW1, Okubanjo O1, Garrett N2, Lalatsa K1, Serrano D1, Summers I2, Moger J2, Stapleton P1, Satchi-Fainaro R3, Schätzlein AG1,4, Uchegbu IF5,6. Pharm Res. 2016 May;33(5):1289-303. doi: 10.1007/s11095-016-1872-x. Epub 2016 Feb 22.
PURPOSE: The blood brain barrier compromises glioblastoma chemotherapy. However high blood concentrations of lipophilic, alkylating drugs result in brain uptake, but cause myelosuppression. We hypothesised that nanoparticles could achieve therapeutic brain concentrations without dose-limiting myelosuppression.
3.Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS04
Jakacki RI1, Cohen KJ1, Buxton A1, Krailo MD1, Burger PC1, Rosenblum MK1, Brat DJ1, Hamilton RL1, Eckel SP1, Zhou T1, Lavey RS1, Pollack IF1. Neuro Oncol. 2016 Mar 22. pii: now038. [Epub ahead of print]
BACKGROUND: The prognosis for children with malignant glioma is poor. This study was designed to determine whether lomustine and temozolomide following radiotherapy and concurrent temozolomide improves event-free survival (EFS) compared with historical controls with anaplastic astrocytoma (AA) or glioblastoma (GBM) and whether survival is influenced by the expression of O6-methylguanine-DNA-methyltransferase (MGMT).
4.A case of Takotsubo cardiomyopathy after chemotherapy.
Malley T1, Watson E1. Oxf Med Case Reports. 2016 Apr 7;2016(4):55-8. doi: 10.1093/omcr/omw014. eCollection 2016.
Here we present the case of a patient with diffuse large B-cell lymphoma who was admitted to hospital for an elective autologous peripheral blood stem cell transplant after cytotoxic treatment with lomustine, cytarabine, cyclophosphomide and etoposide (LACE). On the final day of chemotherapeutic treatment, she developed sudden onset dyspnoea. Electrocardiography confirmed acute antero-lateral T-wave inversion. She went onto have coronary angiography that demonstrated unobstructed coronary arteries. Left ventriculography demonstrated apical ballooning, consistent with Takotsubo (stress) cardiomyopathy. The link between chemotherapy and Takotsubo cardiomyopathy has become increasingly recognized in recent years, although causality remains to be established and the mechanism of action is not yet fully understood.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related DNA Alkylator/Crosslinker Products


CAS 18883-66-4 Streptozotocin

Streptozotocin
(CAS: 18883-66-4)

Streptozotocin is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent. It is commonly used for th...

CAS 50-18-0 Cyclophosphamide

Cyclophosphamide
(CAS: 50-18-0)

Low-dose preferentially deplets Treg cells; An alkylating agent of the nitrogen mustard type with antineoplastic and immunosuppressive activities; Phase I–II

CAS 61825-94-3 Oxaliplatin

Oxaliplatin
(CAS: 61825-94-3)

Oxaliplatin is a platinum-based antineoplastic agent used in cancer chemotherapy that inhibits DNA synthesis by conforming DNA adducts in cancer cells.

CAS 15663-27-1 Cisplatin

Cisplatin
(CAS: 15663-27-1)

Cisplatin induces cytotoxic by interaction with DNA to form DNA adducts which activate several signal transduction pathways, including Erk, p53, p73, and MAPK, ...

Altretamine hydrochloride
(CAS: 2975-00-0)

Altretamine hydrochloride, also called as hexamethylmelamine hydrochloride, is an alkylating agent with apparently less toxicity compared to other cytotoxic dru...

CAS 154-93-8 Carmustine

Carmustine
(CAS: 154-93-8)

Carmustine is  antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA fun...

CAS 41575-94-4 Carboplatin

Carboplatin
(CAS: 41575-94-4)

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism.

CAS 92118-27-9 Fotemustine

Fotemustine
(CAS: 92118-27-9)

Fotemustine is a chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of gu...

CAS 232931-57-6 SJG-136

SJG-136
(CAS: 232931-57-6)

SJG136 is a pyrrolobenzodiazepine dimer with potential antineoplastic activity. SJG-136 binds to the minor groove of DNA and induces interstrand cross-links bet...

CAS 299-75-2 Treosulfan

Treosulfan
(CAS: 299-75-2)

Treosulfan is the prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppresive, and antineoplastic activities. Under physiological ...

CAS 645-05-6 Altretamine

Altretamine
(CAS: 645-05-6)

Altretamine is an anti-neoplastic agent.

CAS 85622-93-1 Temozolomide

Temozolomide
(CAS: 85622-93-1)

Temozolomide is an oral chemotherapy drug.The therapeutic benefit of temozolomide depends on its ability to alkylate/methylate DNA, which most often occurs at t...

Cgp 6809
(CAS: 84069-38-5)

Cgp 6809 is a new methylnitrosoureido-sugar derivative. It is active against a broad spectrum of transplantable tumours in mice and rats. But Phase I clinical t...

CAS 23261-20-3 VAL-083

VAL-083
(CAS: 23261-20-3)

VAL-083 is a bi-functional alkylating agent; inhibit U251 and SF188 cell growth in monolayer better than TMZ and caused apoptosis.

CAS 3778-73-2 Ifosfamide

Ifosfamide
(CAS: 3778-73-2)

Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer.

CAS 55-98-1 Busulfan

Busulfan
(CAS: 55-98-1)

Busulfan is a cell cycle non-specific alkylating antineoplastic agent.

CAS 129580-63-8 Satraplatin

Satraplatin
(CAS: 129580-63-8)

Satraplatin, also known as JM216, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who ha...

CAS 13010-47-4 Lomustine

Lomustine
(CAS: 13010-47-4)

Lomustine (420 μM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively.

CAS 31645-39-3 Palifosfamide

Palifosfamide
(CAS: 31645-39-3)

Palifosfamide is a synthetic mustard compound with potential antineoplastic activity. An active metabolite of ifosfamide covalently linked to the amino acid lys...

Chemical Structure

CAS 13010-47-4 Lomustine

Quick Inquiry

Verification code

Featured Items